Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ScPharmaceuticals Inc.    SCPH

SCPHARMACEUTICALS INC.

(SCPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2020 10/16/2020 10/19/2020 10/20/2020 10/21/2020 Date
8.62(c) 8.8(c) 8.88(c) 8.91(c) 8.78 Last
74 165 110 852 43 226 54 446 4 926 Volume
-1.93% +2.09% +0.91% +0.34% -1.46% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -38,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,69x
Yield 2020 -
Sales 2021 8,08 M - -
Net income 2021 -54,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,96x
Yield 2021 -
Capitalization 243 M 243 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 30,1x
Nbr of Employees 16
Free-Float 91,5%
More Financials
Company
scPharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The Company's products administered subcutaneously through... 
More about the company
Notations Surperformance© of scPharmaceuticals Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about SCPHARMACEUTICALS INC.
10/09SCPHARMACEUTICALS : Provides business update
AQ
10/08SCPHARMACEUTICALS : Provides Business Update
BU
09/18SCPHARMACEUTICALS : Hosting key opinion leader call on furoscix for subcutaneous..
AQ
09/17SCPHARMACEUTICALS : Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) fo..
BU
09/03SCPHARMACEUTICALS : to Participate in Two Upcoming Investor Conferences
BU
08/20SCPHARMACEUTICALS INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
08/13SCPHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition ..
AQ
08/13SCPHARMACEUTICALS INC. : Results of Operations and Financial Condition, Financia..
AQ
08/13SCPHARMACEUTICALS INC. : Reports Second Quarter 2020 Financial Results and Provi..
BU
07/28SCPHARMACEUTICALS : Announces FDA Acceptance of FUROSCIX New Drug Application Re..
AQ
07/27SCPHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
07/27SCPHARMACEUTICALS : Announces FDA Acceptance of FUROSCIX® New Drug Application R..
BU
07/10SCPHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/10SCPHARMACEUTICALS : Appoints Sara Bonstein to Board of Directors
BU
07/02SCPHARMACEUTICALS : Announces furoscix nda resubmission
AQ
More news
News in other languages on SCPHARMACEUTICALS INC.
2019Gerresheimer erst ab 2020 wieder auf Wachstumskurs
More news
Chart SCPHARMACEUTICALS INC.
Duration : Period :
scPharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCPHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 13,25 $
Last Close Price 8,91 $
Spread / Highest target 68,4%
Spread / Average Target 48,7%
Spread / Lowest Target 12,2%
EPS Revisions
Managers
NameTitle
John H. Tucker President, Chief Executive Officer, CFO & Director
Jack A. Khattar Chairman
Mike Hassman Senior Vice President-Technical Operations
John Mohr Senior VP-Clinical Development & Medical Affairs
Mette Kirstine Agger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCPHARMACEUTICALS INC.57.42%243
ABBOTT LABORATORIES24.75%191 855
MEDTRONIC PLC-3.79%146 742
STRYKER CORPORATION5.17%82 934
BECTON, DICKINSON AND COMPANY-13.13%68 484
HOYA CORPORATION18.37%43 912